Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019

Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System

Intrafraction motion synchronization allows real-time tracking visualization and correction for tumor motion during treatment

Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System

April 24, 2019 — Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact System for radiation therapy. This new feature adds intrafraction motion synchronization capabilities to the Radixact System, enabling real-time tracking, visualization and correction for tumor motion during treatment, with the goal of improving dose accuracy and treatment times compared to conventional radiation therapy systems. The Radixact System with Synchrony will be unveiled at the European Society for Radiotherapy & Oncology (ESTRO) meeting, April 26-30 in Milan, Italy.

Originally developed to expand on the CyberKnife System's automatic motion tracking and correction capabilities, Synchrony uses continual image guidance to automatically adjust the movement of the beam in synchronization with the movement of the target volume. The technology is designed to correct for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement, and has the capability to perform fiducial-free tracking for lung indications.

The Radixact System is equipped with a built-in computed tomography (CT) scanner that performs daily imaging before each treatment session. This provides clinicians with information on the shape and position of the tumor, and makes it possible for them to identify and correct for any variations in patient positioning. Clinicians are then able to use Synchrony to automatically synchronize radiation treatment delivery to the moving tumor's location throughout the treatment session. This functionality is designed to provide highly precise radiation dose delivery to tumors that move, such as lung and prostate, and smaller treatment margins around the tumor, minimizing the amount of healthy tissue exposed to high-dose radiation.

Accuray expects to begin shipping the Synchrony technology commercially by the end of calendar year 2019.

Jennifer Smilowitz, Ph.D., clinical professor University of Wisconsin School of Medicine and Public Health, and Fellow of the American Association of Physicists in Medicine (AAPM), has been involved in the development of the Radixact System from its start. She commented, "The introduction of Synchrony for this system will enable clinicians to more easily, and efficiently, deliver precise radiation treatments to tumors that move using image-guided, intensity-modulated radiation therapy (IG-IMRT) with target tracking. In my opinion, this has the potential to expand the way the Radixact System is used, as well as the types of patients who are treated with it."

For more information: www.accuray.com

Related Content

High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...
First Patients Treated With Machine Learning-generated Plans from RayStation 8B
News | Treatment Planning | September 23, 2019
The first-ever patient radiation therapy treatments generated with machine learning in the RayStation treatment...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | September 23, 2019
August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced th
Videos | Radiation Oncology | September 20, 2019
Anne Hubbard, MBA, director of health policy for ASTRO, explains the details and purpose of the proposed Radiation On
Videos | Radiation Therapy | September 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Aktina Showcases New Radiotherapy Patient Immobilization Solutions at ASTRO 2019
News | Patient Positioning Radiation Therapy | September 20, 2019
Aktina Medical introduced several new products at the 2019 American Society for Radiation Oncology (ASTRO) annual...
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology

Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), explains the details of the proposed radiation oncology alternative payment model (APM), and issues ASTRO has raised with the model, at the 2019 ASTRO annual meeting in Chicago.

News | Radiation Oncology | September 18, 2019
During its annual meeting in September, the American Society for Radiation Oncology (ASTRO) issued a response to the...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...